DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Jee Suk | ko |
dc.contributor.author | Kim, Kyung Hwan | ko |
dc.contributor.author | Keum, Ki Chang | ko |
dc.contributor.author | Noh, Sung Hoon | ko |
dc.contributor.author | Lim, Joon Seok | ko |
dc.contributor.author | Kim, Hyo Song | ko |
dc.contributor.author | Rha, Sun Young | ko |
dc.contributor.author | Lee, Yong Chan | ko |
dc.contributor.author | Hyung, Woo Jin | ko |
dc.contributor.author | Koom, Woong Sub | ko |
dc.date.accessioned | 2016-12-01T08:01:30Z | - |
dc.date.available | 2016-12-01T08:01:30Z | - |
dc.date.created | 2016-11-28 | - |
dc.date.created | 2016-11-28 | - |
dc.date.issued | 2016-12 | - |
dc.identifier.citation | JOURNAL OF SURGICAL ONCOLOGY, v.114, no.7, pp.859 - 864 | - |
dc.identifier.issn | 0022-4790 | - |
dc.identifier.uri | http://hdl.handle.net/10203/214606 | - |
dc.description.abstract | Background and ObjectivesTo classify patients with nonmetastatic advanced gastric cancer who underwent D2-gastrectomy into prognostic groups based on peritoneal and systemic recurrence risks. MethodsBetween 2004 and 2007, 1,090 patients with T3-4 or N+ gastric cancer were identified from our registry. Recurrence rates were estimated using a competing-risk analysis. Different prognostic groups were defined using recursive partitioning analysis (RPA). ResultsMedian follow-up was 7 years. In the RPA-model for peritoneal recurrence risk, the initial node was split by T stage, indicating that differences between patients with T1-3 and T4 cancer were the greatest. The 5-year peritoneal recurrence rates for patients with T4 (n=627) and T1-3 (n=463) disease were 34.3% and 9.1%, respectively. N stage and neural invasion had an additive impact on high-risk patients. The RPA model for systemic relapse incorporated N stage alone and gave two terminal nodes: N0-2 (n=721) and N3 (n=369). The 5-year cumulative incidences were 7.7% and 24.5%, respectively. ConclusionsWe proposed risk stratification models of peritoneal and systemic recurrence in patients undergoing D2-gastrectomy. This classification could be used for stratification protocols in future studies evaluating adjuvant therapies such as preoperative chemoradiotherapy. J. Surg. Oncol. 2016;114:859-864. (c) 2016 2016 Wiley Periodicals, Inc | - |
dc.language | English | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject | INTRAPERITONEAL CHEMOTHERAPY | - |
dc.subject | ADJUVANT CHEMOTHERAPY | - |
dc.subject | CURATIVE SURGERY | - |
dc.subject | COMPETING RISK | - |
dc.subject | PHASE-II | - |
dc.subject | S-1 | - |
dc.subject | CHEMORADIOTHERAPY | - |
dc.subject | CARCINOMATOSIS | - |
dc.subject | CELLS | - |
dc.title | Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration | - |
dc.type | Article | - |
dc.identifier.wosid | 000387028900014 | - |
dc.identifier.scopusid | 2-s2.0-84992467397 | - |
dc.type.rims | ART | - |
dc.citation.volume | 114 | - |
dc.citation.issue | 7 | - |
dc.citation.beginningpage | 859 | - |
dc.citation.endingpage | 864 | - |
dc.citation.publicationname | JOURNAL OF SURGICAL ONCOLOGY | - |
dc.identifier.doi | 10.1002/jso.24405 | - |
dc.contributor.nonIdAuthor | Chang, Jee Suk | - |
dc.contributor.nonIdAuthor | Keum, Ki Chang | - |
dc.contributor.nonIdAuthor | Noh, Sung Hoon | - |
dc.contributor.nonIdAuthor | Lim, Joon Seok | - |
dc.contributor.nonIdAuthor | Kim, Hyo Song | - |
dc.contributor.nonIdAuthor | Rha, Sun Young | - |
dc.contributor.nonIdAuthor | Lee, Yong Chan | - |
dc.contributor.nonIdAuthor | Hyung, Woo Jin | - |
dc.contributor.nonIdAuthor | Koom, Woong Sub | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | recurrence | - |
dc.subject.keywordAuthor | gastrectomy | - |
dc.subject.keywordAuthor | survival | - |
dc.subject.keywordAuthor | recursive partition analysis | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | INTRAPERITONEAL CHEMOTHERAPY | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | CURATIVE SURGERY | - |
dc.subject.keywordPlus | COMPETING RISK | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | S-1 | - |
dc.subject.keywordPlus | CHEMORADIOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMATOSIS | - |
dc.subject.keywordPlus | CELLS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.